Ceera Investments LLC Has $1.44 Million Stock Position in Pfizer Inc. $PFE

Ceera Investments LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.4% during the second quarter, Holdings Channel reports. The firm owned 59,567 shares of the biopharmaceutical company’s stock after buying an additional 3,065 shares during the period. Ceera Investments LLC’s holdings in Pfizer were worth $1,444,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Telos Capital Management Inc. boosted its holdings in Pfizer by 9.2% during the second quarter. Telos Capital Management Inc. now owns 27,400 shares of the biopharmaceutical company’s stock valued at $664,000 after purchasing an additional 2,314 shares in the last quarter. MMA Asset Management LLC boosted its holdings in Pfizer by 27.3% during the second quarter. MMA Asset Management LLC now owns 26,757 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 5,744 shares in the last quarter. SS&H Financial Advisors Inc. boosted its holdings in Pfizer by 24.2% during the second quarter. SS&H Financial Advisors Inc. now owns 80,407 shares of the biopharmaceutical company’s stock valued at $1,949,000 after purchasing an additional 15,668 shares in the last quarter. Versor Investments LP boosted its holdings in Pfizer by 561.8% during the second quarter. Versor Investments LP now owns 54,926 shares of the biopharmaceutical company’s stock valued at $1,331,000 after purchasing an additional 46,626 shares in the last quarter. Finally, Plato Investment Management Ltd boosted its holdings in Pfizer by 12.5% during the second quarter. Plato Investment Management Ltd now owns 212,518 shares of the biopharmaceutical company’s stock valued at $5,133,000 after purchasing an additional 23,646 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 1.6%

NYSE:PFE opened at $24.68 on Monday. The stock’s fifty day moving average price is $24.77 and its two-hundred day moving average price is $24.30. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.64. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market cap of $140.29 billion, a price-to-earnings ratio of 13.13, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the business earned $0.60 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PFE. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.24.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.